Is It Time To Reassess Doximity (DOCS) After A Steep Share Price Slide

• If you are wondering whether Doximity at around US$24.18 still reflects its underlying worth, the recent share performance gives you plenty to think about.
• The stock has been choppy, with a 2.5% decline over the last 7 days, a 1.8% gain over the last 30 days, and much steeper moves over longer periods, including a 44.1% decline year to date and a 60.7% decline over the last year.
• Against this backdrop, recent coverage has focused on how investors are reassessing digital health platforms and how market sentiment toward growth oriented healthcare names has shifted. This context helps explain why some shareholders are now paying closer attention to what they are getting for each dollar invested in Doximity.
• Doximity currently scores 5 out of 6 on our valuation checks. This sets up a closer look at how different methods assess its value, and later on, a broader framework that can help you judge whether those valuation signals really fit your own view of the business.

Find out why Doximity's -60.7% return over the last year is lagging behind its peers.

Approach 1: Doximity Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today’s value. It is essentially a way of asking what tomorrow’s cash is worth in today’s dollars.

For Doximity, the model used is a 2 Stage Free Cash Flow to Equity approach, based on current trailing twelve month free cash flow of about $306.6 million. Analysts provide explicit free cash flow estimates for several years, and Simply Wall St then extrapolates further out to build a 10 year path. Under these assumptions, projected free cash flow in 2030 is $447.4 million, with later years continuing to be estimated rather than directly forecast by analysts.

When all those future cash flows are discounted back and combined, the model arrives at an intrinsic value of about $46.67 per share. Compared with a recent share price around $24.18, this DCF output suggests the stock is 48.2% undervalued based purely on these cash flow assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Doximity is undervalued by 48.2%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Doximity.

Approach 2: Doximity Price vs Earnings

For a profitable company like Doximity, the P/E ratio is a useful way to think about valuation because it ties the share price directly to the earnings that support it. In general, higher growth expectations and lower perceived risk can justify a higher P/E multiple, while slower growth or higher risk usually calls for a lower, more conservative multiple.

Doximity currently trades on a P/E of 18.7x, compared with the Healthcare Services industry average of about 27.7x and a peer group average around 32.6x. Simply Wall St’s proprietary “Fair Ratio” for Doximity is 20.4x. This Fair Ratio reflects what the P/E might be expected to look like after factoring in the company’s earnings growth profile, industry, profit margins, market cap and specific risks.

Because the Fair Ratio adjusts for these company specific drivers, it can be more informative than a simple comparison with broad industry or peer averages, which may mix very different business models and risk profiles. Compared with the current 18.7x P/E, the Fair Ratio of 20.4x indicates that Doximity is trading at a discount on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Doximity Narrative

Earlier it was mentioned that there is an even better way to understand valuation, and on Simply Wall St that comes through Narratives. With Narratives, you tell the story you believe about Doximity, link that story to specific forecasts for future revenue, earnings and margins, and end up with a Fair Value that you can compare with the current share price to help you decide whether the stock looks cheap or expensive to you.

A Narrative is your own clear, written view of the business that sits behind the numbers. Instead of only relying on one DCF or P/E output, you can say, for example, that a cautious Doximity view might anchor around a Fair Value near US$25.00 while a more optimistic perspective might sit closer to US$56.00. The Simply Wall St platform then keeps those Narratives live on the Community page, updating them automatically as new earnings, guidance or news arrive.

Because Narratives are visible and easy to compare, you can see how different investors interpret the same facts, decide which assumptions feel closest to your own, and then use that Fair Value versus Price gap as a practical input into when you might add, trim or simply watch the stock.

Do you think there's more to the story for Doximity? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com